Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD

Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic pathology in industrialized countries, affecting about 25% of the general population. NAFLD is a benign condition, however, it could evolve toward more serious diseases, including non-alcoholic steatohepatitis (NASH), fibrosis, cir...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stefania Di Mauro, Alessandra Scamporrino, Agnese Filippello, Antonino Di Pino, Roberto Scicali, Roberta Malaguarnera, Francesco Purrello, Salvatore Piro
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	biomarkers ncRNAs NAFLD Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/d5f97a1e3ef748ca8078245b8e2cf650
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d5f97a1e3ef748ca8078245b8e2cf650
record_format	dspace
spelling	oai:doaj.org-article:d5f97a1e3ef748ca8078245b8e2cf6502021-11-11T17:19:10ZClinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD10.3390/ijms2221119051422-00671661-6596https://doaj.org/article/d5f97a1e3ef748ca8078245b8e2cf6502021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11905https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic pathology in industrialized countries, affecting about 25% of the general population. NAFLD is a benign condition, however, it could evolve toward more serious diseases, including non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and finally, hepatocellular carcinoma (HCC). Liver biopsy is still the gold standard for NAFLD diagnosis. Due to the risks associated with liver biopsy and the impossibility to apply it on a large scale, it is now necessary to identify non-invasive biomarkers, which may reliably identify patients at higher risk of progression. Therefore, several lines of research have tried to address this issue by identifying novel biomarkers using omics approaches, including lipidomics, metabolomics and RNA molecules’ profiling. Thus, in this review, we firstly report the conventional biomarkers used in clinical practice for NAFL and NASH diagnosis as well as fibrosis staging, and secondly, we pay attention to novel biomarkers discovered through omics approaches with a particular focus on RNA biomarkers (microRNAs, long-noncoding RNAs), showing promising diagnostic performance for NAFL/NASH diagnosis and fibrosis staging.Stefania Di MauroAlessandra ScamporrinoAgnese FilippelloAntonino Di PinoRoberto ScicaliRoberta MalaguarneraFrancesco PurrelloSalvatore PiroMDPI AGarticlebiomarkersncRNAsNAFLDBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11905, p 11905 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	biomarkers ncRNAs NAFLD Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	biomarkers ncRNAs NAFLD Biology (General) QH301-705.5 Chemistry QD1-999 Stefania Di Mauro Alessandra Scamporrino Agnese Filippello Antonino Di Pino Roberto Scicali Roberta Malaguarnera Francesco Purrello Salvatore Piro Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD
description	Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic pathology in industrialized countries, affecting about 25% of the general population. NAFLD is a benign condition, however, it could evolve toward more serious diseases, including non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and finally, hepatocellular carcinoma (HCC). Liver biopsy is still the gold standard for NAFLD diagnosis. Due to the risks associated with liver biopsy and the impossibility to apply it on a large scale, it is now necessary to identify non-invasive biomarkers, which may reliably identify patients at higher risk of progression. Therefore, several lines of research have tried to address this issue by identifying novel biomarkers using omics approaches, including lipidomics, metabolomics and RNA molecules’ profiling. Thus, in this review, we firstly report the conventional biomarkers used in clinical practice for NAFL and NASH diagnosis as well as fibrosis staging, and secondly, we pay attention to novel biomarkers discovered through omics approaches with a particular focus on RNA biomarkers (microRNAs, long-noncoding RNAs), showing promising diagnostic performance for NAFL/NASH diagnosis and fibrosis staging.
format	article
author	Stefania Di Mauro Alessandra Scamporrino Agnese Filippello Antonino Di Pino Roberto Scicali Roberta Malaguarnera Francesco Purrello Salvatore Piro
author_facet	Stefania Di Mauro Alessandra Scamporrino Agnese Filippello Antonino Di Pino Roberto Scicali Roberta Malaguarnera Francesco Purrello Salvatore Piro
author_sort	Stefania Di Mauro
title	Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD
title_short	Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD
title_full	Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD
title_fullStr	Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD
title_full_unstemmed	Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD
title_sort	clinical and molecular biomarkers for diagnosis and staging of nafld
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/d5f97a1e3ef748ca8078245b8e2cf650
work_keys_str_mv	AT stefaniadimauro clinicalandmolecularbiomarkersfordiagnosisandstagingofnafld AT alessandrascamporrino clinicalandmolecularbiomarkersfordiagnosisandstagingofnafld AT agnesefilippello clinicalandmolecularbiomarkersfordiagnosisandstagingofnafld AT antoninodipino clinicalandmolecularbiomarkersfordiagnosisandstagingofnafld AT robertoscicali clinicalandmolecularbiomarkersfordiagnosisandstagingofnafld AT robertamalaguarnera clinicalandmolecularbiomarkersfordiagnosisandstagingofnafld AT francescopurrello clinicalandmolecularbiomarkersfordiagnosisandstagingofnafld AT salvatorepiro clinicalandmolecularbiomarkersfordiagnosisandstagingofnafld
_version_	1718432147323224064

Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD

Ejemplares similares